On this page
What each program costs in Mississippi
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $41/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $69/mo | none | too few reviews | Visit | ||
| 4 | Compounded GLP-1 (drug not named) | sale price | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | 12-month plan, $1,163 up front | $97/mo | none | too few reviews | Visit | ||
| 6 | Semaglutide | month to month | $129/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 10 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 11 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 12 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit |
Does the Mississippi State and School Employees' Health Insurance Plan cover GLP-1s for weight loss?
Mississippi's State and School Employees' plan excludes Wegovy and other drugs used for weight loss or obesity. Wegovy and Zepbound are considered only for their other FDA-approved uses, such as obstructive sleep apnea for Zepbound.
Mississippi Department of Finance and Administration
The 2026 plan document lists weight-loss drugs as a plan exclusion.
“Wegovy and other drugs used for weight loss and/or obesity are a plan exclusion.”
https://www.dfa.ms.gov/sites/default/files/Insurance%20Home/Publications/State%20and%20School%20Employees'%20Life%20and%20Health%20Insurance%20Plan%20Documents/2026%20Plan%20Document%20-%20Revised%20July%201,%202026.pdf · read Oct 29, 2026
Mississippi Department of Finance and Administration
Zepbound is considered only for obstructive sleep apnea with obesity.
“Zepbound consideration for coverage will be limited to this indication alone.”
https://www.dfa.ms.gov/sites/default/files/Insurance%20Home/Publications/State%20and%20School%20Employees'%20Life%20and%20Health%20Insurance%20Plan%20Documents/2026%20Plan%20Document%20-%20Revised%20July%201,%202026.pdf · read Oct 29, 2026
Does Mississippi Medicaid cover GLP-1s for weight loss?
Covered, with conditions
Mississippi Medicaid's November 2026 drug list puts Wegovy and Zepbound in its antiobesity class with prior authorization, so it has a coverage path for weight loss. Read from state documents Nov 6, 2026.
What Mississippi Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. Mississippi Division of Medicaid.
WegovyYes
Listed in the antiobesity class with manual prior authorization and review after 12 months. BMI rules were not readable.
“ANTIOBESITY SELECT AGENTS PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA FOUNDAYO (orforglipron) DUR+ liraglutide Provider Education on Prescribing Select Anti-Obesity Agents can be found here All agents MANUAL PA required”
Mississippi Division of Medicaid, Universal Preferred Drug List · Effective Nov 1, 2026 · read Nov 6, 2026
“SAXENDA (liraglutide) orlistat WEGOVY (semaglutide)DUR+ XENICAL (orlistat) ZEPBOUND (tirzepatide)”
Mississippi Division of Medicaid, Universal Preferred Drug List · Effective Nov 1, 2026 · read Nov 6, 2026
“Submission of a manual PA and clinical review may be required when DUR+ electronic PA criteria are not met.”
Mississippi Division of Medicaid, Universal Preferred Drug List · Effective Nov 1, 2026 · read Nov 6, 2026
ZepboundYes
Listed in the antiobesity class with manual prior authorization and review after 12 months. BMI rules were not readable.
“ANTIOBESITY SELECT AGENTS PREFERRED AGENTS NON-PREFERRED AGENTS PA CRITERIA FOUNDAYO (orforglipron) DUR+ liraglutide Provider Education on Prescribing Select Anti-Obesity Agents can be found here All agents MANUAL PA required”
Mississippi Division of Medicaid, Universal Preferred Drug List · Effective Nov 1, 2026 · read Nov 6, 2026
“SAXENDA (liraglutide) orlistat WEGOVY (semaglutide)DUR+ XENICAL (orlistat) ZEPBOUND (tirzepatide)”
Mississippi Division of Medicaid, Universal Preferred Drug List · Effective Nov 1, 2026 · read Nov 6, 2026
“Submission of a manual PA and clinical review may be required when DUR+ electronic PA criteria are not met.”
Mississippi Division of Medicaid, Universal Preferred Drug List · Effective Nov 1, 2026 · read Nov 6, 2026
OzempicUnclear
The incretin section requires a type 2 diabetes diagnosis and no recent GLP-1 therapy for obesity, but it also has a path with no diabetes diagnosis after 84 days of therapy on the drug. No document read says whether that path allows weight loss use, and the separate criteria PDFs could not be read because the agency's regular site is down.
MounjaroUnclear
The incretin section requires a type 2 diabetes diagnosis and no recent GLP-1 therapy for obesity, but it also has a path with no diabetes diagnosis after 84 days of therapy on the drug. No document read says whether that path allows weight loss use, and the separate criteria PDFs could not be read because the agency's regular site is down.
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from Mississippi Division of Medicaid documents. KFF's January 2026 map listed this program as covered; the documents we read agree.
Weight loss
Covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your Mississippi Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed Mississippi Medicaid as "covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether Mississippi Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does Mississippi Medicaid pay for?
61,646 GLP-1 prescriptions in 2025, 33rd of the 50 states and DC, with $69.8 million reimbursed before rebates.
Prescriptions, 2025
61,646
33rd of 51
Medicaid paid
$69.8M
30th of 51, before rebates
Per prescription
$1,132
$1,051 nationally
Weight-loss brands
52%
10th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. Mississippi is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 52% of Mississippi Medicaid's GLP-1 prescriptions in 2025 (32,234). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea.
| Brand | Prescriptions | Share | Medicaid paid |
|---|---|---|---|
| Wegovyapproved for weight management | 31,785 | 52% | $41.5 million |
| Trulicity | 22,721 | 37% | $21.7 million |
| Ozempic | 2,491 | 4.0% | $2.5 million |
| Mounjaro | 2,257 | 3.7% | $2.4 million |
| Victoza | 1,476 | 2.4% | $940,176 |
| Liraglutide (generic) | 300 | 0.5% | $170,082 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
On Medicare in Mississippi?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 2, 2026
Mississippi and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| Mississippi | Covered | 12 | $41/mo |
| Alabama | Not covered | 12 | $41/moWellmedr |
| Arkansas | Not covered | 13 | $41/moWellmedr |
| Louisiana | Not covered | 10 | $41/moWellmedr |
| Tennessee | Covered | 16 | $41/moWellmedr |















